Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy.
Tseng
A
A
Immunodeficiency Clinic, Toronto Hospital, Ontario, Canada.
Conly
J
J
Fletcher
D
D
Keystone
D
D
Salit
I
I
Walmsley
S
S
D000328:Adult; D000740:Anemia / Q000139:chemically induced*; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D006454:Hemoglobins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine